Kite, a Gilead Company (GILD) and Humanigen, Inc., (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The objective of this study is to determine the effect of lenzilumab on the safety of Yescarta. Kite will act as the sponsor of this study and will be responsible for its conduct.
https://finance.yahoo.com/news/kite-humanigen-announce-clinical-collaboration-123100357.html
Mark Cohen, Senior Partner and Chair of the Life Science Practice Group represents Humanigen, Inc. in its intellectual property and commercial transactional matters.
